The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 13, 2018

Filed:

Nov. 13, 2015
Applicants:

Xiang-jin Meng, Blacksburg, VA (US);

Martijn Fenaux, San Mateo, CA (US);

Patrick G. Halbur, Ames, IA (US);

Inventors:

Xiang-Jin Meng, Blacksburg, VA (US);

Martijn Fenaux, San Mateo, CA (US);

Patrick G. Halbur, Ames, IA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/552 (2013.01); C12N 2750/10022 (2013.01); C12N 2750/10034 (2013.01); C12N 2750/10061 (2013.01);
Abstract

The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.


Find Patent Forward Citations

Loading…